- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Michael Wang Discusses the Importance of Biosimilars in Cancer Care
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.
Transcript:
What is your position on biosimilar use inpatients with diffues large B-cell lymphoma? Are you comfortable using biosimilar anticancer therapeutics?
The concept of biosimilars is very powerful and is totally a useful concept. Our healthcare costs are so high, if we don't use biosimilars, our prices will never go down. We cannot afford it. Also biosimilars, in large part, have very good efficacies. I encourage the idea and also the practice of using biosimilars. I am comfortable using biosimilars all the time. When my institution approves of a biosimilar, I have no problem with using it at all. In fact, I'll use it more than the regular high-priced drug.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
